Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

ADHD Drug's hidden effect on brain inflammation revealed

NCT ID NCT07041333

Knowledge-focused Sponsor: Enes Faruk ALTUNKILIÇ Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether methylphenidate, a common ADHD medication, changes levels of brain inflammation markers in children aged 6 to 11. Researchers measured three inflammation-related substances in the blood of 42 children before and after 3 months of treatment. The goal was to understand how the drug might affect inflammation in the brain, not to test if the drug works for ADHD symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

57 people

The number who actually took part.

Started

Jul 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who applied to Bakırköy Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital, diagnosed with Attention Deficit Hyperactivity Disorder, deemed suitable for methylphenidate treatment, and for whom methylphenidate treatment is planned, have been referred to us.

Ages

6 to 11 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. According to DSM-5 TR, the participant must have a diagnosis of "Attention Deficit Hyperactivity Disorder" and have started/be planning to start routine methylphenidate treatment. 2. The participant must be between 6 and 11 years of age. 3. The participant must agree to participate in the study after being informed about it. Exclusion Criteria: 1. The presence of a psychiatric disorder diagnosis other than Attention Deficit Hyperactivity Disorder 2. Having a diagnosis of Attention Deficit Hyperactivity Disorder but not planning to start methylphenidate 3. Being under 6 years of age or over 11 years of age 4. Having organic brain damage, mental retardation, autism spectrum disorder, neurological disease, or a physical illness that affects neurocognitive functions 5. History of alcohol and/or psychoactive substance use 6. Presence of ongoing active infection, allergic disease, and chronic illness 7. Previous use of psychiatric medication. 8. Presence of chronic illness 9. Regular use of medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attention deficit disorder with hyperactivity (ADHD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder Neuroinflammatory Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Attention deficit disorder with hyperactivity (ADHD)

Contacts and locations

Locations

  • Bakırköy Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospita

    Istanbul, Bakırkoy, 34147, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.